Novavax ( NVAX 0.59% ) has been plowing through the early stages of the development of its SARS-CoV-2 vaccine candidate, NVX-CoV2373, and recently announced that it plans to start human clinical trials in mid-May. Previously, it had been less specific, stating that it planned to initiate clinical trials in "late spring."